Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Leukemia - 1 Sept 2017

Falchi L, Kantarjian H M, Verstovsek S

Abstract excerpt

The molecular characterization of myeloproliferative neoplasms, including essential thrombocythemia (ET), has enabled deeper understanding of their pathogenesis. A driver lesion, namely, Janus kinase (JAK)2V617F, calreticulin (CALR) or myeloproliferative leukemia (MPL) gene mutation can be identified in the vast majority of patients. Each of these mutations is associated with distinct clinical features and may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CALR gene
Share to MPL gene
Share to Genomics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Risk Assessment

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Open in PubMed Open full text

Identifiers

PMID: 28529308
DOI: 10.1038/leu.2017.150
PMCID: PMC5989314

Genes

CALR
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.PMID 28529308Read ↗

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Semantic proximity Read ↗

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

A rare CALR variant mutation and a review of CALR in essential thrombocythemia.Semantic proximity Read ↗

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Semantic proximity Read ↗

Comparative thrombotic risk associated with CALR1 , CALR2 , and JAK2 V617F mutations in essential thrombocythemiaSemantic proximity Read ↗

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.Semantic proximity Read ↗

Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.Semantic proximity Read ↗

Genetic Risk Assessment in Myeloproliferative Neoplasms.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.